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Abstract
Introduction. Multiple myeloma (MM) is characterized by
the presence of neoplastic proliferating plasma cells. The
tumor is generally restricted to the bone marrow. The most
common complications include renal insufficiency, hyper-
calcemia, anemia and reccurent infections. The spectrum of
MM neurological complications is diverse, however, in-
volvement of MM in the cerebrospinal fluid (CSF) and lep-
tomeningeal infiltration are rare considered. In about 1% of
the cases, the disease affects the central nervous system
(CNS) and presents itself in the form of localized intrapa-
renchymal lesions, solitary cerebral plasmocytoma or CNS
myelomatosis (LMM). Case report. We presented the clini-
cal course of a 55-year-old man with MM and LMM proven
by malignant plasma cells in the CSF, hospitalized with the
pain in the thoracic spine. His medical history was unevent-
ful. There had been no evidence of mental or neurological
impairment prior to the seizures. Physical examination
showed no abnormalities. After a complete staging,   the di-
agnosis of MM type biclonal gammopathia IgG lambda and
free lambda light chains in the stage III was confirmed. The
treatment started with systemic chemotherapy (with vincris-
tine, doxorubicin plus high-dose dexamethasone – VAD
protocol), radiotherapy and bisphosphonate. The patient
developed weakness, nausea, febrility, dispnea, bilateral
bronchopneumonia, acute renal insufficiency, confusions,
headaches and soon thereafter sensomotor aphasias and
right hemiparesis. The patient was treated with the adequate
therapy including one hemodyalisis. His neurological status
was deteriorated, so Multislice Computed Tomography
(MSCT) of the head was performed and the findings were
normal. Analysis of CSF showed pleocytosis, 26 ele-
ments/mL and increased concentrations of proteins. Cyto-
logical analysis revealed an increased number of plasma cells
(29%).  Electrophoretic analysis of proteins disclosed the
existance of monoclonal components in the serum, urine
and CSF. Immunofixation electrophoretic and quantitative
nephelometric tests confirmed Biclonal multiple myeloma
of IgG lambda and light chain lambda isotypes. Analysis of
neurothropic viruses with ELISA methods was negative.
Once the presence of  LMM was confirmed, the patient re-
ceived intrathecal chemotherapy with methotrexate, cyto-
sine arabinoside, dexamethasone three times a week, and
systemic high doses of dexamethasone iv like a single agent
without craniospinale irradiations. Despite the treatment,
the patient died one month after the diagnosis. Autopsy was
not performed. Conclusion. Presented patient, as well as
most other patients with MM progressing to CNS infiltra-
tion was in the stage III. In addition to the detailed clinical
examination, and all investigations required for MM diagno-
sis and staging of the disease, we introduced the additional
CSF examination and calculation of kappa lambda ratio,
that helped us  make an early diagnosis and prognosis of
MM with LMM. Although LMM had a low prevalence, it
could be more frequent than expected especially in patients
with high risk. CSF examination with positive plasma cells
and abnormal morphology remains the hallmark for  diag-
nosing CNS infiltration.
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Apstrakt
Uvod. Multipli mijelom (MM) karakteriše prisustvo neoplas-
tičnih proliferišućih plazma ćelija, koje se najvećim delom
nalaze u kostnoj srži. Najčešća komplikacija oboljenja je poja-
va renalne insuficijencije, hiperkalcemije, anemije i rekurent-
nih infekcija. Postoje različite neurološke komplikacije kod
bolesnika sa MM, a zahvatanje cerebrospinalnog likvora
(CSF) i leptomeninga je retko. Kod oko 1% slučajeva  bolest
zahvata centralni nervni sistem (CNS) u vidu pojave lokalizo-
vanih intraparenhimskih lezija, solitarnog cerebralnog plaz-
mocitoma ili leptomeningealne mijelomatoze (LMM). Prikaz
bolesnika. U ovom radu prikazali smo bolesnika,  starog 55
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za hematologiju VMA zbog bolova u torakalnom delu kičme,
bez ranijih značajnijih oboljenja i prethodne neurološke sim-
ptomatologije. Nakon učinjenog ispitivanja dokazan je MM
tipa biklonalne gamapatije (IgG tipa lambda i slobodnih lakih
lanaca tipa lambda) u III kliničkom stadijumu. Nakon prime-
ne hemioterapije prema protokolu VAD (vinkristin, doksoru-
bicin plus visoke doze deksametazona), uz radioterapiju i bis-
fosfonate dolazi do razvoja slabosti, muke, povišene telesne
temperature, dispneje, obostrane bronhopneumonije, akutne
bubrežne insuficijencije, konfuzije i  glavobolje, a brzo posle
toga i do senzomotorne afazije i desnostrane hemipareze.
Primenjena je adekvatna terapija i jedna hemodijaliza, ali je
zbog daljeg pogoršanja neurološkog statusa učinjena multis-
lajsna kompjuterska tomografija (MSCT) glave, čiji je nalaz
bio uredan. U daljem toku, zbog sumnje u zahvaćenost CNS
osnovnim oboljenjem učinjena je lumbalna punkcija. Anali-
zom likvora viđen je povećan broj ćelijskih elemenata, pove-
ćana koncentracija proteina i oko 29% patoloških plazma će-
lija. Elektroforezom proteina seruma, urina i likvora potvrđe-
na je monoklonska komponenta, a imunofiksacijom dokaza-
no da se radi o biklonalnoj gamapatiji (IgG tipa lambda i slo-
bodni laki lanaci tipa lambda), uz negativan nalaz neurotrop-
nih virusa, čime je potvrđeno prisustvo LMM. Dalje lečenje
sprovođeno je trojnom intratekalnom terapijom uz visoke
doze deksametazona, bez primene kraniospinalne iradijacije.
Uprkos primenjenom lečenju bolesnik je umro mesec dana
nakon dijagnoze MM, a obdukcija nije urađena. Zaključak.
Većina bolesnika sa MM, kao i prikazani bolesnik, kod kojih
je dokazana LMM, nalaze se u III kliničkom stadijumu. Pored
detaljne kliničke obrade potrebne za dijagnozu i stepenovanje
MM učinili smo ispitivanje likvora i odredili kapa/lambda od-
nos, što je značajno pomoglo u ranoj dijagnozi LMM. Iako je
prevalencija  LMM niska, može se češće dokazati kod boles-
nika sa MM koji imaju faktore visokog rizika. Ispitivanje lik-
vora sa dokazanim plazma ćelijama koje imaju abnormalnu
morfologiju ostaje najznačajniji dijagnostički test za dijagnozu
LMM.
Ključne reči:
multipli mijelom; neoplazme, metastaze; mozak;
dijagnoza, diferencijalna; imunoglobulini.
Introduction
Multiple myeloma (MM) is characterized by monoclonal
paraprotein production, lytic lesions and increased plasma
cells in the bone marrow
 1. The most common complications
include renal insufficiency, hypercalcaemia, anemia and recur-
rent infection
 2, 3. Patients often have neurological complica-
tions, either due to metabolic disorders such as hypercalcae-
mia, uremia and hyperviscosity or due to peripherial neuropa-
thy, spinal cord compression and cranial nerve infiltration. The
most common are cord compression and peripheral neuropa-
thy
 4. Involvement of the CNS in MM is very rare. Leptome-
ningeal involvement in MM is the most frequent type of CNS
MM reported in the literature. Approximately 70 cases have
been reported and published in the literature in the last 20
years
 5. Despite aggressive systemic and local treatment, the
outcome was poor
 6. In this study we reported the neurological
symptoms and signs, imaging, cerebrospinal fluid (CSF) find-
ings and the clinical course of a 55-year-old man with MM
and CNS myelomatosis (LMM). LMM was proven by malig-
nant plasma cells, protein electrophoresis and immunofixation
tests of the CSF in the presence of CNS symptoms.
Case report
A 55-year-old man was hospitalized because of thoracic
spine pain. His medical history had been uneventful. There
had been no evidence of mental or neurological impairment
prior to the seizures. Physical examination showed no abnor-
malities. Initial blood chemistry analyses showed mild anemia
(hemoglobine 102 g/L), elevated erythrocyte sedimentation
rate of 62 mm/h, fibrinogen 3.59 g/L, increase in serum creat-
inine, 178 µmol/L, and blood urea nitrogen (BUN) 10.5
mmol/L. The level of β2-microglobulin was highly increased,
7.99 mg/L, compared to the normal range of 0.7–1.8. Serum
albumin and calcium concentrations were normal, but protein-
uria was 4.34 g/24 h. Serum protein electrophoresis (PE) on a
“Sebia“ cappillarys/hydrasys demonstrated a spike in the
gamma fraction, as well as in the beta region of urine and CSF
PE. Immunofixation electrophoresis (IFE) confirmed that se-
rum M-component belonged to IgG lambda isotype, with con-
centration of 38.6 g/L on admission, suppressed IgA (< 0.33
g/L) and IgM (< 0.16 g/L), as well as increased value of total
lambda free chain (9.2 mg/L). Urinary homogen M-fraction
was due to owerflow type of proteinuria and existence of free
light chain (FLC) of immunoglobulin (Ig) molecules or Bence
Jones proteins. FLC lambda concentration was dramatically
elevated to 2490 mg/L as compared to the reference interval of
5.7–26.2 mg/L. Bone marrow aspiration revealed plasma cell
infiltration (40%), confirming the diagnosis of multiple mye-
loma. Magnetic resonance imaging of thoracic spine showed a
pathology fracture of Th8 with a decrease in bone intesity near
the thoracic spine. Craniogram revealed multiple lytic skull le-
sions. After a complete staging, we retained the diagnosis of
MM type biclonal gammopathia (IgG lambda and free lambda
light chains) in the III B clinical stage (CS), and soon, we in-
troduced systemic chemotherapy (VAD protocol) combining
vincristine, doxorucin and dexamethasone with bisphospho-
nate and radiotherapy (single shoot of Th8). Soon thereafter,
the patient developed confusions, headaches, weakness, nau-
sea, febrility, dispnea and later sensomotor aphasias and right
hemiparesis. After complete examinations (lab analysis, chest
rentgenography, echocardiography, microbiology analysis of
sputum, bronchoscopy) we concluded that the patient devel-
oped bilateral bronchopneumonia and acute renal insuffi-
ciency. The patient was treated with adequate antibiotics and
other therapy including one hemodyalisis. Because his neuro-
logical status deteriorated, we did multislice computed tomog-
raphy of the head, which was normal. CSF analysis showed
pleocytosis (26 elements/mL), increased concentrations of
proteins in the CSF, without hypoglicorahia. Cytological
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Marjanović S, et al. Vojnosanit Pregl 2012; 69(2): 209–213.
(Figure 1). Analysis of neurotropic viruses with ELISA meth-
ods was negative twice.
Fig. 1 – High-power view of cytological findings of
cerebrospinal fluid (CSF): binuclear plasma cells and
mononuclear plasma cells are seen. Other cells are
lymphocytes and monocytes
Increased concentration of all three immunoglobulins in
CSF and elevated CSF/serum albumin ratio were also de-
tected. Protein imunofixation electrophoresis showed a homo-
gene fraction in CSF for all three immunoglobulines, as mono-
or oligoclonal bands (Figure 2), but in serum only for IgG. Be-
sides that, the calculation of kappa/lambda free light chain ra-
tio was decreased (0.006). The concentration of all the men-
tioned proteins was determined by immunonephelometry
(“SIEMENS“ DADE BNII) method (Table 1).
Fig. 2 – Immunofixation electrophoresis in serum (S)
and cerebrospinal fluid (CSF)
Table 1
Concentrations of immunoglobulines, Ig fragments and
albumin in serum and synovial fluid
Body fluid Values (Ref. values)
Cerebrospinal fluid (CSF)
IgG (mg/L) 330 0–5)
IgM (mg/L) 6.3 0–1
IgA (mg/L) 33 0–5
Albumin 788 0–1
Serum (s)
IgG (mg/L) 26.7 8–17
albumin (g/L) 35.5 37–53
albumin quotient 22.2 < 5.4
IgG index 0.55 < 0.7
IgG de novo
Free kappa (mg/L) 14.9
Free lambda (mg/L) 2490
k/l ratio 0.006 0.26–1.65
CSF/s protein ratio
IgA index 0.26 0–0.15
IgM index 2.4 0–0.1
After the diagnosis of LMM, the patient received intra-
thecal chemotherapy with 20 mg methotrexate, 20 mg cyto-
sine arabinoside and 20 mg dexamethasone three times a
week, with systemic high doses of dexamethasone iv as a
single agent without craniospinal irradiations. In spite of the
treatment, the patient died one month after being diagnosed.
Autopsy was not performed.
Discussion
Patients with MM often have neurologic complications,
either due to metabolic disordes such as hypercalcemia, ure-
mia and hyperviscosity or due to peripheral neuropathy, spi-
nal radiculopathies, spinal cord compression and cranial
nerve infiltration. While infiltration of leptomeninges by
various malignancies including acute lymphocytic leukemia,
diffuse lymphomas, breast cancer and small-cell lung cancer
with the rates of 2%–75% is well-known, invasion of the
CNS in MM is rare, either as presumed localized intraparen-
chymal lesions, solitary cerebral plasmocytom or as LMM.
The overall incidence of CNS involvement was only about
1%. At the time of LMM diagnosis, there was a diffuse array
of neurologic symptoms and signs, including cerebral
symptoms, neurologic findings referable to cranial neuropa-
thies and to the spinal cord or spinal nerve roots. Presenting
symptoms of CNS involvement most commonly include
headaches, limb weakness, mental changes and cranial nerve
palsies 
7–10. Approximately 70 cases, mostly case reports,
have been reported in the English-language literature in the
past century. The largest series, 23 patients out of 2,000 pa-
tients with LMM was reported by Schluterman et al. 
5 from
the University of Arcansas Medical Center over a 13-year
period. All 23 patients presented with symptoms suggestive
of CNS involvement that prompted neurological investiga-
tions: 15 patients had cerebral symptoms, including head-
aches, mental status changes and seizures, 12 had cranial
neuropathy, while 18 patients had motor and sensory distur-
bances due to spinal nerve root involvement. The median
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survival from the MM diagnosis to the development of LMM
was 3 months. The 23 cases had intrathecal chemotherapy
twice a week with methotrexate, cytosine arabinoside plus
hydrocortisone. Cytologic sterilization of CSF was achived
in 11 patients. Systemic chemotherapy was given to 18 pa-
tients and 5 patients who did not receive systemic chemo-
therapy eather died soon after the diagnosis or refused fur-
ther treatment. The authors concluded that the reasons un-
derlying a relative paucity of CNS invasion by MM in com-
parison with other tumors remain unknown, but might be the
result of the underlying biological characteristics, or lack
thereof, of malignant plasma cells
 5.
Pizzuti et al. 
11 reported 3 cases and made a retrospec-
tive review of 18 cases with MM infiltration. They found
that meningeal involvement occurred in patients with ini-
tially stage III MM in 85% of cases, and it was associated
with the occurrence of plasma cell leukaemia in 20% of
cases. The most frequent neuorological signs were confusion
(60%), altered consciousness (25%), gait disorder (25%) and
cranial nerve (25%) palsy.
If survival was prolonged, the prevalence of LMM
might be higher. There are 2 reported cases of patients with
MM in which LMM developed after 7 and 10 years sug-
gesting that it can occur after a longer period. However, it
does not confirm that a long survival time might increase the
prevalence, and a large series over several years might be
needed to confirm this statement
 8. Involvement of the CNS
in MM is determined by the detection of malignant plasma
cells in CSF, with the presence of symptoms suggestive of
MM
 5. Dispenzieri and Kyle 
10 in a review of the neurologi-
cal aspects of MM, classified intracranial plasmacytomas or
myelomas into 4 groups: those extending from the skull
pressing inward; those growing from the dura mater or the
leptomeninges; those arising from the mucous membranes of
a nasopharyngeal plasmacytoma; and intraparenchymal le-
sions without evidence of extencion from any of the other 3
sites.
Movsas et al. 
12 reported cases with sixth-nerve palsies
as a presenting sign for intracranial plasmacytoma in MM.
Kyle and Dispenzieri 
9 noted that the involvement of cra-
nial nerves and their divisions is a rare complication of
MM, which occurs most commonly at the time of a pro-
gressive disease. Other rare type of presentation was a 42-
year-old woman with Bence-Jones-type MM who devel-
oped ocular abnormalities as described by Tuncbilek et
al
 13. Haegelen et al. 
14 reported a 72-year-old woman pre-
sented with headaches and left hemiparesis, and was diag-
nosed with dural plasmacytoma; further investigations
showed systemic MM. Specific magnetic resonance imag-
ing suggestive of CNS invasion included leptomeningeal
contrast enhancement and the evidence of meningeal-based
lesions sometimes masquerading as intraparenchymal le-
sions 
14. MSCT of the head in our case raport showed no
abnormality.
CSF examination remains the definitive test for diag-
nosing LMM, usually exhibiting pleocytosis or elevated
protein content plus positive cytologic findings
 15. Cytology
showed eritrocytes, lymphocytes, and monocytes, but there
were also 29% of pleomorphic plasma cells. Pathologic, bi-
nucelar plasma cells were also seen.
We systematically measured immunoglobulin levels in
sera and CSF samples, and decreased concentration of IgG
was expected to the level of 16 g/L after introducing the
therapy. Elevated CSF/serum albumin ratio and a significant
decrease in filtration capability of blood brain bariere was
due to involvement of the CNS in MM. Findings of homo-
genic fractions in CSF only for IgA and IgM but not in sera,
could be connected with their probable local production in-
side CNS, similar as in cases of Ig intrathecal synthesis
 16.
Besides that, extremely low free k/L ratio, as a marker for
fast progression and short survival time was also con-
firmed
 17, 18. These results are in complete concordance with
others
 19 that imply the quantifications of serum free light
chains and calculating FLC k/ ratio as a useful diagnostic
tool for the course and survival.
Merelli et al. 
20 reported 3 cases with IgD MM. They de-
tected and identified IgD paraprotein in CSF and concluded
that there was a correlation between the presence of parapro-
tein in CSF and the possible neurological involvement.
The presence of CNS symptoms in MM will usually
lead to further investigations, including CSF examination
and radiological testing for restaging if the patient was
known (diagnosed) with MM. Detection of malignant plasma
cells in the CSF is considered the hallmark of the diagnosis.
At diagnosis of LMM, intrathecal chemotherapy was given
once or twice weekly ranging from 3 to 12 doses, depending
on the clinical neurologic response. Systemic treatment con-
sisted of intermediate–dose chemoterapy, high-dose che-
moterapy followed by autologous stem cell transplant or
followed by allogeneic stem cell transplant. In this case, a
standard VAD therapy was introduced with bisphosphonate
and radiotherapy (single shoot of Th8). After diagnosis of
LMM, we administered three times a week intrathecal che-
motherapy with 20 mg methotrexate, 20 mg cytosine ara-
binoside and 20 mg dexamethasone, with systemic high
doses of dexamethasone iv like a single agent without cra-
niospinal irradiations.
The prognosis of patients with LMM is poor, despite
aggressive local and systemic treatment. The median survival
has been estimated at approximately 4–5 months. Even when
sterilization of CSF was achieved, patient’s survival was
limited by the aggressive systemic disease. The most com-
mon are high-risk cytogenetic abnormalities in both bone
marrow and CSF, plasmablastic morphology, extramedullary
manifestations, plasma cell leukemia and high serum lactate
dehydrogenase levels. Our previous experience with other Ig
isotypes of MM could elicit consideration, that, in this case
report, the existence of the second LCD lambda type with
CNS involment was more significant for fast progression and
worse prognosis. Thus, leptomeningeal seeding is a con-
comitant of aggressive MM. We believe that the treatment of
LMM is indicated, given its potential for symptomatic relief
and improvement in the quality of life. Better understanding
of the biology of LMM may allow prospective and earlier
recognition and treatment of patients at risk for this compli-
cation.Volumen 69, Broj 2 VOJNOSANITETSKI PREGLED Strana 213
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Conclusion
Presented patient, as well as most other patients with
MM progressing to CNS infiltration was in the stage III.
Besides detailed clinical examination, with all the required
investigations for MM diagnosis and staging of the dis-
ease, we introduced additional CSF examination and cal-
culation of kappa/lambda ratio, that would help us in
making an early diagnosis and prognosis of MM with
LMM. Although LMM has a low prevalence, it could be
more frequent than expected, especially in high-risk pa-
tients. CSF examination with positive plasma cells and ab-
normal morphology remains the hallmark for the diagnosis
of CNS infiltration.
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